CPXX News Alert Celator Pharma (CPXX) 1.75 12/25/2014 07:36:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celator Pharma (CPXX) 1.75 $CPXX

Celator Pharmaceuticals gets European Patent Allowance for taxane prodrug nanoparticle delivery technology
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) reported on Thursday that it has received the European Patent Office's allowance for its "Improved Taxane Delivery System" with patent protection for formulations combining docetaxel and other taxanes with molecularly targeted agents.
CPXX: 1.75 (unch)

Celator® Pharmaceuticals Receives European Patent Allowance on Nanoparticle Delivery Technology
PR Newswire - Thu Dec 18, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the application of European patent number 2,222,278 was allowed by the European Patent Office. The new patent, "Improved Taxane Delivery System," covers the Company's proprietary taxane prodrug nanoparticle delivery technology and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, which is based on this innovative approach to drug delivery. Celator is currently applying its proprietary CombiPlex technology to drug combinations incorporating targeted agents, such as a combination of docetaxel with a heat shock protein (Hsp90) inhibitor where extended and simultaneous exposure of the two agents to solid tumors at the optimized drug ratio is expected to significantly enhance the efficacy of this combination. This should help establish the broad applicability of the CombiPlex platform in the development of combination cancer therapies. This patent provides protection until November 2028.
CPXX: 1.75 (unch)

Celator® Pharmaceuticals Presents Data on CPX-351 at the 56th American Society of Hematology Annual Meeting
PR Newswire - Wed Dec 10, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data on its lead product candidate, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, held December 6-9, 2014.
CPXX: 1.75 (unch)

Celator® Pharmaceuticals Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351
PR Newswire - Mon Dec 01, 7:30AM CST
EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML), has completed a planned safety review and recommended that the study continue as planned without any modifications.
CPXX: 1.75 (unch)

Celator® Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Nov 24, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014.
CPXX: 1.75 (unch)

Celator Pharmaceuticals' (CPXX) CEO Scott Jackson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 2:02PM CST

CPXX: 1.75 (unch)

Celator Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:22PM CST

CPXX: 1.75 (unch)

Celator® Pharmaceuticals Announces Business Update And Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the third quarter ended September 30, 2014.
CPXX: 1.75 (unch)

Celator® Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference on November 19, 2014 at 4:10 p.m. ET in New York City.
CPXX: 1.75 (unch)

Celator Pharma reports November 13
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:13PM CST

CPXX: 1.75 (unch)

Celator® Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 13, 2014
PR Newswire - Tue Nov 04, 11:20AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Thursday, November 13, 2014, at 4:30 p.m. ET to report third quarter 2014 financial results.
CPXX: 1.75 (unch)

Celator(R) Pharmaceuticals to Present on Liposome Delivery Systems at 2014 American Association of Pharmaceutical Scientists Annual Meeting
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Dr. Lawrence Mayer, President, Founder and Chief Scientific Officer of Celator, will present at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego, California on Wednesday, November 5, 2014, as part of the Advances in Lipid-Based Delivery Systems for Transdermal, Oral, and Parenteral Administered Drugs session. Dr. Mayer's presentation is scheduled at 2:50 p.m. PST/5:50 p.m. EST.
CPXX: 1.75 (unch)

Celator(R) Pharmaceuticals Announces Completion of Its Public Offering and the Exercise in Full of Option to Purchase Additional Units of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Tue Oct 28, 9:49AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the closing of an underwritten public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters' over-allotment option to purchase up to an additional 991,673 units. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The shares of common stock and the warrants are immediately separable and were issued separately. The warrants have an exercise price of $3.58 per whole share and have a term of five years. The net proceeds to Celator, after underwriting discounts and commissions and estimated offering expenses, were approximately $13.5 million.
CPXX: 1.75 (unch)

Celator(R) Pharmaceuticals Announces Phase 3 Clinical Study of CPX-351 Achieved Target Enrollment in High Risk (Secondary) Acute Myeloid Leukemia
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the target enrollment of 300 patients has been achieved in the company's multicenter, randomized, open-label Phase 3 study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the current standard of care, conventional cytarabine and daunorubicin therapy (7+3) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). The study randomized the 300 patient ahead of schedule and will remain open for a short time to enable all patients currently in the process of referral and evaluation to complete enrollment into the study.
CPXX: 1.75 (unch)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 11:45AM CDT

IHT: 2.86 (+0.17), AIRM: 43.03 (-0.10), MGT: 0.60 (-0.01), NCT: 4.68 (-0.02), BBW: 19.35 (+0.25), ADHD: 4.00 (+0.24), CAB: 51.06 (-0.12), IPCM: 45.95 (-0.19), VII: 1.83 (+0.38), MTRN: 34.11 (+0.05), UTEK: 18.31 (+0.08), CPXX: 1.75 (unch), BRP: 24.01 (+1.15), SHLM: 40.37 (+0.11), NPTN: 3.51 (+0.02), IBIO: 0.68 (-0.04), YELP: 53.00 (-0.36), CLRO: 9.74 (-0.02), VPCO: 1.30 (-0.01), INFN: 15.22 (+0.05)

Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the pricing of an underwritten public offering of 6,611,150 shares of common stock and warrants to purchase up to 661,115 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The gross proceeds to Celator from this offering are expected to be approximately $12.9 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company and exclusive of any warrant exercises. The shares of common stock and the warrants are immediately separable and will be issued separately. The warrants will be exercisable upon issuance at an exercise price of $3.58 per whole share and will have a term of five years. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 991,673 units to cover over-allotments, if any. The offering is expected to close on or about October 28, 2014, subject to customary closing conditions.
CPXX: 1.75 (unch)

Celator Pharmaceuticals to issue public offering of units
M2 - Mon Oct 20, 6:33AM CDT
Pharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) said on Friday that it plans to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
CPXX: 1.75 (unch)

Celator(R) Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Fri Oct 17, 11:58AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock. Roth Capital Partners and National Securities Corporation are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CPXX: 1.75 (unch)

Celator(R) Pharmaceuticals to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference
GlobeNewswire - Fri Sep 19, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at BioCentury's 21 Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 3:30 p.m. ET in New York City.
CPXX: 1.75 (unch)

Celator(R) Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on September 17, 2014
GlobeNewswire - Wed Sep 17, 8:27AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Celator team, led by Scott Jackson, Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell this afternoon. The ceremony is in recognition of the company listing on NASDAQ within the past year and to celebrate recent successes, including the development progress made with lead compound, CPX-351, and the decision to broaden potential clinical applications of the Company's proprietary CombiPlex(R) technology platform.
CPXX: 1.75 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 78

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitfarms and Riot Platforms Reach Important Settlement Agreement

Updated Category News Views 57

Bitfarms Ltd and Riot Platforms Reach Settlement on Disputes Today, Bitfarms Ltd (NASDAQ:BITF), a leading player in the cryptocurrency mining field, announced that it has successfully settled disputes with Riot Platforms (NASDAQ:RIOT). This important settlement seeks to resolve various conflicts that existed between the two companies, although the specific details of...

Continue Reading
Peer To Peer Network Unveils Strategic Insights for PTOP Labs

Updated Category News Views 195

Peer To Peer Network Reveals Insights on PTOP Intelligence Labs Peer To Peer Network (OTC: PTOP) has taken a decisive step towards revolutionizing investor communication and engagement with the introduction of PTOP Intelligence Labs. During a recent call, the company’s newly appointed division president, Derek McCarthy, shared insights into the innovative AI-driven...

Continue Reading
Firsthand Technology Fund Reports Third Quarter Financial Performance

Updated Category News Views 234

Firsthand Technology Value Fund Financial Overview Firsthand Technology Value Fund, Inc. (OTCQB: SVVC), a publicly trading venture capital fund focused on technology and cleantech investments, has provided an update on its financial performance for the recent quarter. As of the end of September, the Fund reported net assets amounting to $296,547, translating to $0.04 per...

Continue Reading
Nanit Unveils Innovative AI Sleep Score Tailored for Babies

Updated Category News Views 310

Nanit Launches Groundbreaking AI Sleep Score for Infants Nanit has introduced an innovative Sleep Score feature aimed specifically at helping parents enhance their babies' sleep quality. This groundbreaking technology translates complex clinical-grade sleep data into a single, easy-to-understand number. Parents will now have access to a powerful tool that demystifies...

Continue Reading
The Surge of the Manufacturing Execution System Market

Updated Category News Views 155

Introduction to the Manufacturing Execution System Market The global manufacturing execution system (MES) market is experiencing remarkable growth, fueled by the rising trend of digital transformation across various manufacturing sectors. As industries evolve, the demand for real-time data and efficient management of production processes is becoming increasingly critical....

Continue Reading